Argenica Therapeutics (ASX: AGN) — Company Overview, News & Financial Data
Argenica Therapeutics is a biopharmaceutical company pioneering neuroprotective therapeutics for stroke recovery.
Argenica Therapeutics
Argenica Therapeutics is a clinical-stage biotechnology company focused on developing novel neuroprotective therapeutics to minimize brain damage following stroke and other acute brain injuries. Based on intellectual property developed at The University of Western Australia and the Perron Institute for Neurological and Translational Science, the company is advancing its lead drug candidate to protect brain cells and reduce cell death in acute ischaemic stroke patients. The therapeutic is currently in clinical testing across emergency departments in Australia, with additional research programs targeting traumatic brain injury, hypoxic ischaemic encephalopathy, and neurodegenerative conditions.
Snapshot
Products and/or services of Argenica Therapeutics
- Acute Ischaemic Stroke Therapeutic: A clinical-stage cationic peptide neuroprotective drug designed to protect brain tissue and reduce cell death following acute ischaemic stroke, undergoing Phase 2 clinical trials across emergency departments in Australia.
- Traumatic Brain Injury Treatment: Preclinical development of neuroprotective peptide therapies formulated to reduce neuroinflammation and cellular damage following severe traumatic brain injuries, targeting early intervention protocols for emergency care.
- Hypoxic Ischaemic Encephalopathy Drug: Preclinical research programs focused on administering neuroprotective therapeutic peptides to reduce brain damage caused by oxygen deprivation during birth in newborn infants facing hypoxic ischaemic encephalopathy.
- Pre-Hospital First Responder Administration: Development of stable emergency field administration protocols enabling paramedics and first responders to deliver neuroprotective therapeutics immediately upon suspecting stroke, minimizing brain injury prior to hospital arrival.
- Surgical Ischaemia Neuroprotection: Preclinical evaluation of targeted neuroprotective therapeutic candidates to mitigate perioperative cerebral brain tissue injury and ischaemic events during complex cardiovascular surgeries and high-risk surgical procedures.
- Neurodegenerative Disease Research: Early stage translational research targeting chronic neurodegenerative conditions, including Alzheimer disease models, to inhibit neurotoxic protein aggregation, reduce neuroinflammation, and preserve overall neuronal cell integrity.
Argenica Therapeutics executive team
- Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.CEO, MD & Director
- Ms. Emma WaldonCFO & Company Secretary
- Prof. Bruno Philip MeloniChief Scientific Officer